Dual function of Pin1 in NR4A nuclear receptor activation: Enhanced activity of NR4As and increased Nur77 protein stability  by van Tiel, Claudia M. et al.
Biochimica et Biophysica Acta 1823 (2012) 1894–1904
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamcrDual function of Pin1 in NR4A nuclear receptor activation: Enhanced activity of
NR4As and increased Nur77 protein stability
Claudia M. van Tiel, Kondababu Kurakula, Duco S. Koenis, Erik van der Wal, Carlie J.M. de Vries ⁎
Department of Medical Biochemistry, Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105AZ, Amsterdam, The NetherlandsAbbreviations: CHX, cycloheximide; CK2, protein k
domain; DCOH, dimerization cofactor for hepatocyte nu
S-transferase; LBD, ligand-binding domain; Pin1, peptid
PPIase, Peptidyl-prolyl isomerase; pSer/pThr-Pro, phospho
threonine; TBB, 4,5,6,7-tetrabromobenzotriazole
⁎ Corresponding author at: Department of Medical B
Medical Center, University of Amsterdam, Meibergdree
Netherlands. Tel.: +31 205665152; fax: +31 20691551
E-mail address: c.j.devries@amc.nl (C.J.M. de Vries).
0167-4889/$ – see front matter © 2012 Elsevier B.V. Al
doi:10.1016/j.bbamcr.2012.06.030a b s t r a c ta r t i c l e i n f oArticle history:
Received 20 January 2012
Received in revised form 14 June 2012
Accepted 29 June 2012
Available online 10 July 2012
Keywords:
Protein–protein interaction
Protein stability
Transcription factor
NR4A nuclear receptorsNur77, Nurr1 and NOR-1 form the NR4A subfamily of the nuclear receptor superfamily and have been shown
to regulate various biological processes among which are cell survival and differentiation, apoptosis, inﬂam-
mation and metabolism. These nuclear receptors have been proposed to act in a ligand-independent manner
and we aim to gain insight in the regulation of NR4A activity. A yeast two-hybrid screen identiﬁed the
peptidyl-prolyl isomerase Pin1 as a novel binding partner of NR4As, which was conﬁrmed by
co-immunoprecipitation. Pin1 enhances the transcriptional activity of all three NR4A nuclear receptors and
increases protein stability of Nur77 through inhibition of its ubiquitination. Enhanced transcriptional activity
of NR4As requires theWW-domain of Pin1 that interacts with the N-terminal transactivation domain and the
DNA-binding domain of Nur77. Most remarkably, this enhanced activity is independent of Pin1 isomerase ac-
tivity. A systematic mutation analysis of all 17 Ser/Thr-Pro-motifs in Nur77 revealed that Pin1 enhances pro-
tein stability of Nur77 in an isomerase-dependent manner by acting on phosphorylated Nur77 involving
protein kinase CK2-mediated phosphorylation of the Ser152-Pro153 motif in Nur77. Given the role of Nur77
in vascular disease and metabolism, this novel regulation mechanism provides perspectives to manipulate
Nur77 activity to attenuate these processes.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The NR4A receptor family belongs to the nuclear hormone receptor
superfamily and consists of three highly homologousmammalianmem-
bers known as Nur77 (also indicated as NR4A1, NGFI-B, TR3), Nurr1
(NR4A2) and NOR-1 (NR4A3, MINOR, Nor1). The NR4A transcription
factors were ﬁrst described as early response genes expressed upon
stimulation by multiple growth factors and have been shown to play a
role in the regulation ofmetabolism in liver, skeletalmuscle and adipose
tissue and cardiovascular disease [1–3]. Basic cellular processes such as
differentiation, apoptosis, proliferation and stress responses are modu-
lated by NR4A nuclear receptors [4–6]. We have demonstrated that
Nur77 and Nurr1 inhibit the formation of smooth muscle-rich vascular
lesion formation and exhibit an anti-inﬂammatory function in macro-
phages [2,7–9].
Like all nuclear receptors, Nur77, Nurr1 and NOR-1 consist of a
carboxy-terminal ligand-binding domain (LBD), an amino-terminalinase CK2; DBD, DNA-binding
clear factor 1; GST, glutathione
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l rights reserved.domain mediating ligand-independent coactivator recruitment and
a central DNA-binding domain (DBD). This DBD is extremely similar
among the NR4A receptors (94% amino acid sequence identity). The
ligand‐binding domains also show substantial amino acid similarity
(approximately 65%), whereas the amino-terminal domains are
more divergent (approximately 30% similarity) [10]. All three NR4A
receptors bind as monomers to the response element NBRE
(AAAGGTCA) or as NR4A heterodimers or homodimers to the palin-
dromic NurRE (TGATATTTX6AAAGTCCA) in the promoters of speciﬁc
target genes [11]. Nur77 and Nurr1, but not NOR-1, also form
heterodimers with the Retinoid X Receptor in the presence of reti-
noids and thus can modulate the activities of a subclass of retinoid
response elements [12]. NR4A receptors are referred to as orphan
receptors, because as yet no ligands have been identiﬁed, which is
in line with structural analyses of the ligand‐binding domains of
Nurr1 and Nur77 showing that the putative ligand-binding pocket is
ﬁlled with bulky aromatic and hydrophobic residues [13,14]. These
structural analyses also revealed that the canonical coactivator cleft,
through which most nuclear receptors interact with the LxxLL motif
of coregulators, is hydrophobic rather than hydrophilic in Nur77
and Nurr1. As a consequence, the interaction of NR4As with
coregulators most likely does not involve such LxxLL motifs. For the
NR4A subfamily the activation function (AF)-1 domain, which is lo-
calized in the amino-terminal domain, appears to be most important
for transcriptional activation and cofactor recruitment. Direct inter-
action with the AF-1 domain of Nur77 has been shown for the
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corepressors SHP and CRIF1. The corepressor SMRT has been shown to
interact in a CaMKIV-dependent way with the ligand‐binding domain
of Nur77 [10,15–19].
Peptidyl-prolyl isomerases (PPIases) form an evolutionary conserved
group of proteins that promote the cis/trans isomerization of the peptide
bond preceding speciﬁc proline residues [20]. Peptidyl-prolyl cis/trans
isomerase 1 (Pin1) belongs to the parvulin subfamily of PPIases and
is unique in that it is the only PPIase that speciﬁcally recognizes phos-
phorylated proline-directed serine/threonine (pSer/pThr-Pro) motifs
[21–23]. These Pin1-induced conformational changes have profound
effects on the properties of many Pin1 substrates, like protein phos-
phorylation, enzyme activity, protein localization, protein interaction,
transcriptional activity and protein stability [24–26]. This allows Pin1
to play an important role in a wide range of cellular processes such
as regulation of the cell cycle [27,28], the cellular response to DNA
damage [29], and in transcriptional regulation [30,31]. Pin1 is a protein
of 163 amino acids and comprises an amino-terminalWWdomain that
is involved in protein–protein interaction and a carboxy-terminal
PPIase domain [22,23]. A number of Pin1-interacting proteins are tran-
scription factors, including c-Jun, NF-κB, p53, β-catenin, PPARγ and
steroid receptor coactivator (SRC)3 [32,33].
In the current study, we sought to identify novel coregulatory pro-
teins of the NR4A receptors and identiﬁed Pin1 as a novel coactivator
of Nur77, Nurr1 and NOR-1, which has so far only been described for
Nur77 [34]. Our yeast two-hybrid revealed four and a half
LIM-domain 2 (FHL2) as a novel corepressor of NR4As [35].We demon-
strate that Pin1 interacts with and enhances the transcriptional activity
of Nur77 in a PPIase-independent manner and enhances the stability of
Nur77 protein in a PPIase-dependent manner by acting on the phos-
phorylated Ser152-Pro153 motif in Nur77. Pin1 enhances the expression
of the Nur77 target gene enolase 3. Altogether these data reveal a novel
Pin1-mediated regulation mechanism of Nur77 activity and suggest
that association of Pin1 with Nur77 plays a role in the regulation of vas-
cular disease and metabolism.
2. Materials and methods
2.1. Plasmids
The cDNA encoding the N-terminal domain of hNOR-1 (Genbank
D78579), coding for amino acids 2–290, was cloned into the pGBKT7
vector (Clontech). hNur77 cDNA (GenBank D49728, bp 8–1947),
hNurr1 cDNA (Genbank X75918, bp 73–2310) and hNOR-1 (bp
513–2872) were cloned into the pRRL-cPPt-X2-CMV-PreSIN vector [36]
and amino-terminally epitope tagged by cloning into the pCMV-Myc
vector (Clontech). Pin1 was N-terminally tagged by cloning from the
pGADT7 library vector into the pCMV-HA vector (Clontech), cloned
into the pRRL-cPPt-X2-CMV-PreSIN vector and amino-terminally tagged
with His6-GST by cloning into the pETM-30 vector. Plasmids encoding
GST-CK2α and GST-CK2α′ have been described before [37] and were
obtained via Addgene (plasmids 27083 and 27084). The luciferase
reporter plasmids containing three copies of NurRE or NBRE have been
described before [11,38]. Severalmutants of Nur77 and Pin1were gener-
ated by site-directed mutagenesis using the QuickChange site-directed
mutagenesis method (Stratagene) according to the manufacturer's in-
struction. The primers used to generate themutants are listed in Supple-
mental Tables S1 and S2. All constructs were veriﬁed by sequencing.
Short hairpin RNA plasmids targeting CK2α and Ck2α′ genes from The
RNAi Consortium (TRC) [39] were obtained from Sigma-Aldrich. The
human shRNA oligo sequences are listed in Supplemental Table S3.
2.2. Yeast two-hybrid assay
A smooth muscle cell cDNA library was constructed from 0.5 μg of
poly A+ RNA from activated smooth muscle cells [40] using theMatchmaker library construction and screening kit (Clontech)
according to the manufacturer's instructions. The bait construct
pGBKT7-NOR-1 was transformed into the Saccharomyces cerevisiae
strainAH109 (Clontech) using the lithium-acetatemethod. Subsequently
these yeast cells were transformedwith the pGADT7-smoothmuscle cell
cDNA library and interacting clones were isolated on selective syn-
thetic drop-outmediumbased on growth in the absence of tryptophan,
leucine, and histidine in presence of 30 mM 3-amino-1,2,4-triazole
(3-AT, Sigma). False positives were eliminated based on their interac-
tion with the negative control (empty pGBKT7) vector. The plasmids
of the positive cloneswere isolated and sequenced. TheDNA sequences
were then characterized by BLAST analysis against the NCBI database
to determine the identity of the potential NOR-1 interacting proteins.
2.3. Cell culture
HEK293T cellswere cultured inDulbecco'sModiﬁed Eagle'smedium
supplemented with 10% (v/v) fetal bovine serum (FBS) and penicillin
and streptomycin (Invitrogen). Human smooth muscle cells were
explanted from umbilical cord arteries [40]. Cells were cultured in
M199 containing 10% FBS and penicillin and streptomycin. Smooth
muscle cells were used at passages 5 to 7 and were characterized by
SM α-actin expression (1A4, DAKO) and showing uniform ﬁbrillar
staining.
2.4. Generation of lentiviral particles and transduction
Recombinant lentiviral particles encoding Nur77, shNur77 and
Pin1 were produced, concentrated and titrated as described before
[7]. Smooth muscle cells were incubated with recombinant lentivirus
for 24 h after which the medium was refreshed and the cells were
cultured for another 72 h. Transduction efﬁciency was determined
by immunoﬂuorescence.
2.5. Co-immunoprecipitation assay
HEK293T cells were seeded in a 6-well plate and co-transfected with
1 μg of the appropriate constructs by calcium phosphate precipitation
using the CalPhos Mammalian Transfection Kit (Clontech). Medium
was refreshed 24 h after transfection and cells were lysed 48 h after
transfection in 400 μl ice-cold pull-down buffer (50 mM Tris–HCl, pH
7.4, 100 mM NaCl, 10% (v/v) glycerol, 1% (v/v) Nonidet P-40, 10 mM
NaF, 1 mM Na3VO4 supplemented with Complete protease-inhibitor
cocktail (Roche Applied Science)). Cell lysates were pre-cleared for 1 h
at 4 °C with protein A-Sepharose (GE Healthcare) and then incubated
overnight with the pull-down antibody and protein A-Sepharose. The
precipitate was washed 3 times with pull-down buffer, and bound pro-
teins were eluted by boiling in SDS-loading buffer before electrophoresis
on 12% SDS-polyacrylamide gels. After protein transfer, PVDF mem-
branes (Millipore) were incubated with appropriate primary antibodies
and ﬂuorescently conjugated secondary antibodies, followed by scan-
ning using Odyssey Infrared Imaging System (LI-COR Biosciences
GmbH). Antibodies applied in this study: anti-HA (12CA5; RocheApplied
Science), anti-Pin1 (Calbiochem), anti-Nur77 (M210) and anti-c-Myc
(both Santa Cruz Biotechnology).
2.6. GST pulldown
Escherichia coli-expressed glutathione S-transferase (GST)-His6-Pin1
was bound to glutathione Sepharose 4B (GE Healthcare), followed by
the addition of Nur77, which was generated by in vitro transcription
and translation using the TNT T7Quick Coupled transcription/translation
system according to the manufacturer's instructions (Promega). The
bound proteins were resolved on 12% SDS‐polyacrylamide gels and
detected by Western blot analysis.
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Fig. 1. Pin1 interacts with Nur77, Nurr1 and NOR-1. (A) HEK293T cells expressing
Nur77, Nurr1 or NOR-1 and HA-mock or HA-Pin1 were immunoprecipitated with
anti-HA antibodies. Immunoprecipitates were resolved by SDS-PAGE and processed
by Western blot analysis using the indicated antibodies. Input, total lysate used for im-
munoprecipitation. (B) His6-GST-Pin1 or His6-GST-DCOH was bound to glutathione
sepharose and incubated with in vitro transcribed and translated Nur77. The complexes
were resolved by SDS-PAGE, followed by Western blotting using anti-Nur77 (upper
panel) and anti-His6 (lower panel) antibodies. Input, in vitro transcribed and translated
Nur77. IP, immunoprecipitation; WB, Western blot. (C) Pin1 co-localizes with Nur77,
Nurr1 and NOR-1 in the nucleus. The cellular localization of Nur77, Nurr1, NOR-1 and
Pin1 was determined in smooth muscle cells by immunoﬂuorescence using anti-Nur77,
anti-Nurr1 and anti-NOR-1 (green, left column) and anti-Pin1 (red, second column) anti-
bodies. The cells were counterstained with Hoechst (right column). Co-localization of
Nur77, Nurr1 or NOR-1 and Pin1 is shown by the overlay of the ﬁrst two columns (third
column, co-localization indicated in yellow). Antibody isotype controls are shown in
Supplemental Fig. S1. Pin1 is present in the nucleus and to a lesser extent in the cyto-
plasm, whereas Nur77 is only expressed in the nucleus indicating that Nur77 and Pin1
interact only in the nucleus and that Pin1 does not affect cellular localization of Nur77.
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For immunoﬂuorescence, cells were cultured on glass coverslips.
Smoothmuscle cellswere transducedwith the appropriate lentiviruses.
The cells were ﬁxed with 4% (w/v) paraformaldehyde in PBS, perme-
abilized with 0.5% (v/v) Triton X-100 and Nur77, Nurr1, NOR-1 and
Pin1 were detected using the appropriate antibody. As secondary anti-
bodies the Alexa Fluor 488 goat anti-rabbit IgG or Alexa Fluor-568
goat anti-mouse were used, the nuclei were stained with Hoechst (all
Molecular Probes).
2.8. Luciferase assay
HEK293T cells were transfected with NurRE or NBRE luciferase re-
porter plasmids together with pCMV-Myc-Nur77 (mutants) and
pCMV-HA-Pin1 (mutants) or pCMV-HA-mock. pRL-TK renilla report-
er plasmid (Promega) was co-transfected as an internal control.
Luciferase activity was determined 24 h after transfection using the
dual-luciferase reporter assay system (Promega) according to the
manufacturer's protocol.
2.9. Semi-quantitative RT-PCR
Total RNA was prepared with Total RNA mini kit (Bio-Rad) from
cells. cDNA synthesis was performed with iScript (Bio-Rad), followed
by real-time PCR using the MyIQ system (Bio-Rad). Human enolase 3
primers: 5′-GAAGAAGGCCTGCAACTGTC-3′ (sense) and 5′-ACTTGCG
TCCAGCAAAGATT-3′ (anti-sense) were used for real-time PCR. Acidic
ribosomal phosphoprotein P0 was determined as an internal control
for cDNA content of the samples.
2.10. Knockdown of Pin1 and Nur77
Human Pin1 small interfering RNA (siRNA) was designed using the
Whitehead Institute (Cambridge, MA) siRNA selection program [41].
HEK293T cells were transfected with siRNA duplexes (Ambion Inc.)
at 100 nM ﬁnal concentrations using Oligofectamine (Invitrogen)
according to the manufacturer's instructions. The Pin1 target sequence
was 5′-GCCGAGUGUACUACUUCAA-3′ and control transfections were
with siRNA against 5′-CAGACGAGCCUUGCUCGUC-3′. The knockdown
of Pin1 was veriﬁed by Western blotting using an antibody directed
against Pin1 as primary and IRDye 800CW goat anti-rabbit (LI-COR
Biosciences GmbH) as secondary antibody. Pin1 expression was quan-
tiﬁed using the Odyssey Infrared Imaging System. shNur77 and control
shRNA were generated as described [7].
2.11. Protein stability assay
HEK293T cells were transfected with pCMV-Myc-Nur77 and
pCMV-HA-Pin1 or pCMV-HA-mock. After 24 h of transfection themedi-
um was refreshed and the cells were treated with cycloheximide
(50 μg/ml) or vehicle (DMSO) for 4–16 h. In some cases the cells were
also treated withMG132 (10 μM). Nur77 protein levels weremeasured
by Western blot analysis using mouse monoclonal c-Myc antibody
(Santa Cruz) and quantiﬁed on Odyssey Infrared Imaging System.
α-Tubulin (Cedarlane) was used as a control for protein loading.
2.12. CK2 kinase assay
GST-CK2α and GST-CK2α′ were puriﬁed from bacterial lysates as
described [37]. Nur77 or Nur77-S152A was immunoprecipitated from
HEK293T cells as described above. Immunoprecipitated Nur77(mutant)
was treated for 30 min at 30 °Cwith calf intestinal alkaline phosphatase
(Invitrogen). After washing the immunoprecipitated Nur77(mutant)
was incubated for 20 min at 30 °C with a mixture of GST-CK2α
and GST-CK2α′ in CK2 assay buffer (50 mM Tris–HCl, pH 7.5, 150 mMNaCl, 10 mM MgCl2, 100 μM ATP) in the presence of 1 μCi γ-32P-ATP.
To stop the reaction, the samples were boiled in 5 μl SDS-loading
buffer before electrophoresis on a 12% SDS-polyacrylamide gel.
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Biosciences).2.13. Statistical analysis
Data are reported as Mean±SD and were analyzed with the un-
paired Student t-test. Values of Pb0.05 were considered statistically
signiﬁcant (*Pb0.05, **Pb0.01, ***Pb0.001 in the ﬁgures).A NurRE
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3.1. Pin1 is a novel binding partner of the NR4A nuclear receptors
To understand the regulation of NR4A nuclear receptor activity, we
aimed to identify new binding partners and performed a yeast
two-hybrid screen. We and others reported that NR4A receptor expres-
sion is induced in activated vascular smooth muscle cells and for that
reason a cDNA library was generated from (activated) smooth muscle
cells to identify novel interacting proteins [40,42]. The amino-terminalNurr1
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scriptional activity of these nuclear receptors and for cofactor recruit-
ment [10]. The amino-terminal domain of Nur77 gave unspeciﬁc
background colonies in the yeast two-hybrid system therefore the
amino-terminal region of NOR-1 was used as bait to screen the smooth
muscle cell cDNA library. From the colonies that were able to grow
under selective conditions, we isolated two independent cDNAs
containing an open reading frame encoding full-length peptidyl-prolyl
cis/trans isomerase Pin1 (Genbank NM_006221). To verify the interac-
tion found in the yeast two-hybrid screen we performed a
co-immunoprecipitation experiment. Full-length Nur77 and HA-tagged
Pin1 were expressed in HEK293T cells and Nur77 was efﬁciently
co-immunoprecipitated with Pin1. A similar experiment was performed
using full-length NOR-1 and Nurr1, showing that NOR-1 and Nurr1 also
interact with Pin1 (Fig. 1A).
To demonstrate direct interaction between Pin1 and Nur77, we
performed aGST-pull-down assay. As shown in Fig. 1B in vitro transcribedNNur77
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Immunoﬂuorescence using vascular smooth muscle cells revealed
that Nur77 located in the nucleus. As expected, Pin1 co-localized with
Nur77 in the nucleus and was also detected in the cytoplasm. Pin1
does not change cellular localization of Nur77 and similar results
were obtained for Nurr1 and NOR-1 (Fig. 1C).
3.2. Pin1 is a coactivator of NR4A receptors
To investigate whether Pin1 binding inﬂuences the transcriptional
activity of Nur77, HEK293T cells were transfected with plasmids
encoding Nur77 and Pin1 together with luciferase reporter constructs.
Pin1 signiﬁcantly increased the transcriptional activity of Nur77,
Nurr1 and NOR-1 when assayed with the NurRE-containing reporter
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transcriptional activity is not due to an increase inNur77mRNAbecause
Pin1 does not affect Nur77 mRNA levels (Supplemental Fig. S2B).
Nur77 is known to induce the expression of enolase 3, which is me-
diated through an NBRE in the enolase 3 promoter [43]. To assess
whether Pin1 also enhances Nur77 activity in human vascular smooth
muscle cells, wemeasured enolase 3 expression. As expected, Nur77 ro-
bustly enhanced enolase 3 expression, which was further increased by
Pin1 (Fig. 2C). The effect of endogenous Pin1 andNur77 is substantiated
using speciﬁc siRNA against Pin1 (Supplemental Fig. S2C, D) and Nur77.
Knockdown of Nur77 or Pin1 resulted in a signiﬁcant decrease in eno-
lase 3 expression (Fig. 2D). In agreement with the luciferase data, Pin1
increases Nurr1-mediated enolase 3 expression. Unexpectedly, in
smooth muscle cells Pin1 does not enhance NOR-1 induced enolase 3
expression, indicating a cell-type speciﬁc function of Pin1. Our data in-
dicate that Pin1 increases both NBRE-driven monomeric and
NurRE-mediated dimeric NR4A transcriptional activity and therefore
may be considered as a coactivator of Nur77, Nurr1 and NOR-1.
3.3. Pin1 interacts with the N-terminal and DNA-binding domains of Nur77
To assess which region of Nur77 interacts with Pin1, Nur77mutants
were assayed in co-immunoprecipitation experiments (Fig. 3A, B). Pin1**
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in HEK293T cells expressing the indicated proteins and the NurRE luciferase reporter (N=4
blotting using anti-Nur77, anti α-tubulin and anti-Pin1 antibodies, showing similar Nur77
corresponding Renilla luciferase activity and are expressed as mean±SD, ***Pb0.001. Protein
myc-Nur77 together with HA-mock or wild-type or mutant HA-Pin1were immunoprecipita
processed by Western blotting using anti-Nur77 and anti-Pin1 antibodies. The Pin1W34A
Pin1-mediated stimulation of Nur77 activity.is co-immunoprecipitated by full-length Nur77, the DNA-binding do-
main (DBD, aa 264–354) and the separate amino-terminal domain of
Nur77 (N-term, aa 1–264), but not by the ligand-binding domain
(LBD, aa 355–598) (Fig. 3B). Because Pin1 did not bind the LBD, we de-
termined whether this domain was indeed dispensable for the
coactivation of Nur77. The Nur77 mutant lacking the LBD (ΔLBD) is
transcriptionaly active and Pin1 still enhanced the activity of ΔLBD
(Fig. 3C). These experiments demonstrate that the Nur77 LBD is not re-
quired for coactivation and that Pin1 interacts with both the
amino-terminal region and the DNA‐binding domain of Nur77.
3.4. Pin1 coactivation of Nur77 does not require PPIase activity
Pin1 is a PPIase that isomerizes pSer/pThr-Pro motifs. It comprises
an N-terminal WW domain that is involved in protein-protein interac-
tion and a carboxy-terminal PPIase domain. It has been shown that
alanine-substitution of Trp34 (W34A) results in a Pin1-variant with a
defective WW domain [44,45], whereas substitution of Lys63 or Cys113
in the catalytic domain (K63A and C113A) yields a Pin1 mutant that
lacks PPIase activity [45,46]. As expected, Pin1W34A did not enhance
Nur77 transcriptional activity, as thismutant is defective in Nur77 bind-
ing. However, both Pin1K63A and Pin1C113A still enhanced Nur77
transcriptional activity of Nur77 (Fig. 4B), demonstrating that theC
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variant does not interact with Nur77 and disruption of the WW-domain abolishes
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with these data, the Pin1K63A mutant still binds Nur77, whereas
Pin1W34A does not (Fig. 4C).
3.5. Pin1 increases Nur77, but not Nurr1 or NOR-1 protein stability
Pin1 has been shown to enhance Nur77 protein stability [34], and
we tested whether Pin1 also affects the protein stability of Nurr1 and
NOR-1. To this end, we treated cells expressing Nur77, Nurr1 or
NOR-1 with the protein synthesis inhibitor cycloheximide (CHX). In
the absence of Pin1, CHX decreased the Nur77 and Nurr1 protein
levels, whereas NOR-1 protein levels remained the same for up to
16 h (Fig. 5). In the presence of Pin1, Nur77 protein remained stably
present during the CHX treatment. In contrast, Nurr1 protein was
not stabilized by Pin1.
To test which functional domain of Pin1 is important for the en-
hanced stability of Nur77, we repeated the CHX experiment in cells ex-
pressing Nur77 and mutant Pin1. As expected, Pin1W34A, which is
impaired in Nur77 binding, does not stabilize Nur77 in the presence of
CHX. Furthermore, Pin1K63A and Pin1C113A, both of which lack the
catalytic activity, also do not stabilize Nur77 protein (Fig. 6A, B). It is
concluded that Pin1 enhances Nur77 protein stability for which also
PPIase activity is crucial. It should be noted that in the experiments inNur77
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Fig. 5. Pin1 increases Nur77, but not Nurr1 or NOR-1 protein stability. HEK293T expressing N
indicated times and Nur77 (A), Nurr1 (B) and NOR-1 (C) expression levels were analyzed b
NOR-1 protein expression, normalized to α-tubulin expression is depicted as a percentage o
as mean±SD, ***Pb0.001.which NR4A activity is measured, we designed the experimental set
up such that the protein levels of the NR4Aswere similar in the absence
and in the presence of Pin1. Our experiments demonstrate for the ﬁrst
time that Pin1 has a dual function in Nur77 activation; WW-domain
mediated interaction of Pin1 enhances the transcriptional activity of
Nur77 and the combined action of theWW-domainwith the PPIase ac-
tivity of Pin1 increase Nur77 protein stability.
3.6. Pin1 positively regulates Nur77 stability by inhibiting its ubiquitination
We next investigated whether Nur77 stability is regulated through
proteasomal degradation. Cells expressing Nur77 were treated with
CHX in combination with the proteasome inhibitor MG132. As de-
scribed above, CHX decreased Nur77 protein levels in the absence of
Pin1, however, MG132 treatment inhibited the CHX-mediated decrease
in Nur77 levels (Fig. 6C, D), indicating that the ubiquitin-proteasomal
degradation pathway is involved in regulation of Nur77 stability. To fur-
ther investigate the effect of Pin1 on Nur77 stability, we expressed
Nur77 together with HA-ubiquitin in the presence and absence of
Pin1. Nur77 ubiquitination, as shown after immunoprecipitation of
ubiquitin-conjugated proteins and subsequent Western blotting with
an anti-Nur77 antibody, was only observed in the absence of Pin1,
When Pin1 was co-expressed ubiquitinated Nur77 could hardly be0 4 8 12 16
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stability by inhibiting its ubiquitination.
3.7. Pin1 increases Nur77 protein stability by acting on pSer152-Pro
After demonstrating that the increased stability of Nur77 is depen-
dent on the PPIase activity of Pin1, we investigated which Ser/Thr-Pro
motif in Nur77 is targeted by Pin1. The amino-acid sequence of Nur77
contains 17 serine or threonine residues that are followed by a pro-
line residue; the Pin1 consensus Ser/Thr-Pro motif. As yet it isunknown whether any of these Ser/Thr-Pro motifs are phosphorylat-
ed in Nur77. To identify the Pin1 target site, Nur77 mutants were gen-
erated in which these serine/threonine residues were changed into
alanine residues (Supplemental Fig. S4A). Each of the mutants was
analyzed in the protein stability assay. We found that Pin1 enhances
the stability of all Nur77 mutants except for Nur77-S152A (mutant
5, Fig. 6F and Supplemental Fig. S4) It should be noted that the tran-
scriptional activity of Nur77-S152A and the Nur77-variant in which
all 17 Pin1 consensus site are alanine-substituted (Nur77-MutAll)
are still enhanced by Pin1 when measured under conditions that
1902 C.M. van Tiel et al. / Biochimica et Biophysica Acta 1823 (2012) 1894–1904protein levels remain similar (Supplemental Fig. S5). So far,
phosphorylation of Ser152 of Nur77 has not been reported, however,
in silico analysis revealed a potential protein kinase CK2 site at this
residue. Therefore, potential involvement of CK2 in Pin1 mediated
Nur77 stability was tested. Inhibition of CK2 by its inhibitor
4,5,6,7-tetrabromobenzotriazole (TBB) abolished the ability of Pin1
to stabilize Nur77 (Fig. 7A, B), whereas the MAPK-inhibitor
(PD98059) did not affect Nur77 stability. In addition, knockdown of
both catalytic subunits of CK2 (CK2α and CK2α′) using shRNA also
inhibited the ability of Pin1 to stabilize Nur77 (Fig. 7C and**
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mutant Nur77 was determined by phosphorimaging. Equal immunoprecipitation of wild-ty
amino-acid sequence of the three NR4A nuclear receptors, showing that NOR-1 does not con
kinase CK2 consensus site.Supplemental Fig. S6). To establish direct phosphorylation of Nur77
by CK2, Nur77 was immunoprecipitated from HEK293T cells and
was, after dephosphorylation with alkaline phosphatase, incubated
with the catalytic subunits of CK2 (CK2α and CK2α′) in the presence
of radioactive ATP. As shown in Fig. 7D, under these conditions Nur77
is a substrate for CK2, whereas the mutant Nur77-S152A is not. These
data indicate that Pin1 increases Nur77 protein stability by isomeriz-
ing Pro153 when it is preceded by CK2-phosphorylated Ser152. Inter-
estingly, Nurr1, which is not stabilized by Pin1, does contain the
Ser152-Pro motif, but this is not in a CK2 consensus site, whereas***
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pe Nur77 and Nur77-S152A was determined by Western blotting. (E) Alignment of the
tain the Ser152-Pro motif. In Nurr1 this motif is conserved, however, it is not in a protein
1903C.M. van Tiel et al. / Biochimica et Biophysica Acta 1823 (2012) 1894–1904NOR-1, which is not degraded in the presence of CHX does not con-
tain the Ser152-Pro motif (Fig. 7E). The dual function of Pin1 in
Nur77 activation is visualized in a scheme in Supplemental Fig. S7.
4. Discussion
Nur77, Nurr1 and NOR-1 have been classiﬁed as orphan nuclear re-
ceptors since ligands have as yet not been identiﬁed although several
small-molecule drugs have been described that enhance NR4A activity
[47,48]. Because of the regulatory role of NR4A receptors in vascular dis-
ease and metabolism [2,7,49], it is crucial to understand how NR4A
transcriptional activity is regulated. The amino-terminal domain of
Nur77 has been shown to be important for cofactor binding
[10,15–19] and we therefore carried out a yeast two-hybrid screen to
identify novel coregulators of Nur77, Nurr1 and monomeric NOR-1.
We demonstrated that four and a half LIM-domain-2 (FHL2) is a novel
corepressor of Nur77 [35] and now report that the PPIase Pin1 binds
all 3 NR4A receptors and,most importantly, enhances the transcription-
al activity of bothmonomeric and dimeric Nur77, Nurr1 andNOR-1. The
ligand-binding domain of Nur77 is not required for this coactivation as
Pin1 is still able to enhance the transcriptional activity of a Nur77 vari-
ant lacking this domain (Fig. 3C). The physiological relevance of the in-
teraction between Pin1 and Nur77 is underpinned by the observation
that Pin1 enhances the expression of the Nur77 target gene enolase 3.
It is demonstrated that Pin1 PPIase activity is not required to en-
hance Nur77 activity as was shown with the PPIase-negative variants
Pin1K63A and Pin1C113A. Although in general the PPIase activity of
Pin1 is essential to change the transcriptional activity of target proteins,
the dispensability of the PPIase activity has been described before for
Pin1-dependent modulation of Stat3 and PPARγ activity [32,50]. The
Pin1 interaction with and activation of Nur77 are mediated solely by
the WW domain of Pin1, which binds both the amino-terminal and
the DNA-binding domain of Nur77 (Fig. 3B). The exact mechanism un-
derlying Pin1-mediated coactivation of NR4As is as yet unknown. It is
most likely that Pin1 binding to NR4As recruits other coactivators that
enhanceNR4A activity or Pin1 binding to NR4Asmay displace corepres-
sor proteins of Nur77 (Supplemental Fig. S7 for a schematic of the
model). In contrast, Chen et al. proposed that the PPIase activity of
Pin1 is crucial to bind Nur77, however, this conclusion was based on
treatment of Nur77 with a phosphatase [34] whereas we demonstrate
using Nur77-MutAll, a variant in which all 17 Pin1 consensus binding
site are alanine substituted, still binds and becomes activated by Pin1
(Supplemental Fig. S5D, E).
We show that Pin1 speciﬁcally enhances protein stability of Nur77,
whereas protein levels of Nurr1 and NOR-1 are not affected. This obser-
vation underscores the direct effect of Pin1 in activation of NR4A activ-
ity independent of protein stabilization. Although the catalytic activity
of Pin1 is not involved in increasing Nur77 transcriptional activity, its
PPIase activity is essential to enhance Nur77 stability and we identiﬁed
Ser152-Pro as the Pin1 target site in Nur77. Pin1 has been demonstrated
to exhibit little PPIase activity on non-phosphorylated Ser/Thr-Pro se-
quences, therefore we postulated that Ser152 is very likely phosphory-
lated prior to Pin1 modulation. It has been described that Nur77 is
highly phosphorylated on multiple sites, however, the knowledge on
which amino-acids are actually phosphorylated bywhich kinases is lim-
ited [51]. Nur77 is phosphorylated at Ser351 in the DNA-binding domain
by RSK and Akt [52,53] and at Ser140 by the MAPK pathway [54]. Fur-
thermore, Nur77 was shown to be phosphorylated by JNK somewhere
in the ﬁrst 122 amino-acid residues of Nur77 [55]. Phosphorylation of
Ser152 has, however, not yet been described. In silico analysis revealed
in addition to a potential MAPK site at Thr143, two potential CK2 sites
at Ser152 and at Ser431 in Nur77. Inhibition or knockdown of CK2
abolished the capability of Pin1 to enhance Nur77 stability, whereas in-
cubation with a selective MAPK (MEK) inhibitor did not (Fig. 7). Fur-
thermore, we show that Nur77 is a substrate for CK2, whereas
Nur77-S152A is not (Fig. 7D). We therefore conclude that Pin1 acts onthe CK2-phosphorylated Ser152-Pro153 motif in Nur77 to induce a con-
formational change resulting in enhanced stability of this nuclear recep-
tor (Supplemental Fig. S7). These data are in line with the observation
that Pin1 is not able to enhance the stability of Nurr1, which does con-
tain the Ser152-Pro Pin1-motif, however this is not in a CK2 consensus
site. Interestingly NOR-1, which does not comprise the Ser152-Pro
motif, is not degraded in the presence of CHX and Pin1 does not affect
this (Figs. 5 and 7E). Previously, it has been shown that CK2 canmediate
inhibition of smooth muscle cell proliferation requiring phosphoryla-
tion of cAMP response element binding protein (CREB) [56]. We pro-
pose that Nur77 is another CK2 substrate to modulate smooth muscle
cell growth. Pin1 enhances Nur77 most likely by changing the confor-
mation of Nur77 by isomerization on pSer152, thereby making the pro-
tein less prone to ubiquitination and subsequent degradation, as we
show that ubiquitination of Nur77 is inhibited by Pin1 (Fig. 6E). This ob-
servation is in line with the observation that acetylation of Nur77 by
p300 results in inhibition of ubiquitination and thus increased stability
[15]. Pin1 isomerization may make Nur77 more accessible to p300
acetylation, resulting in a more stable protein. Of note, Chen et al. [34]
identiﬁed distinct Ser-Pro motifs as potential interaction sites for Pin1,
more speciﬁcally Ser 95 (corresponding with our mutant 3), Ser 140
(mutant 4) and Ser 431 (mutant 10). We did not observe any effect
on Nur77 activity/stability after alanine substitution of these residues
(Fig. 6 and Supplemental Figs. S4 and S5). At this moment we have no
satisfying explanation for this discrepancy.
Interestingly, although the presence of the CK2-phosphorylated
Ser152-Pro motif is essential for Pin1-mediated enhancement of Nur77
stability, it is not required to enhance Nur77 activity, as mutant 5
(Nur77-S152A) is still coactivated by Pin1 (Supplemental Fig. S5; note
that protein levels are similar under these conditions). This is in line
with the ﬁnding that Pin1 is also able to enhance the activity of Nurr1
and NOR-1 that lack the CK2-motif. Taken together, Pin1-dependent
coactivation of Nur77 is distinct from Pin1-dependent increase in
Nur77 protein stability and together this dual effect of Pin1 onNur77 re-
sults in enhanced Nur77 transcriptional activity.
Given the role of the NR4A nuclear receptors in vascular disease
andmetabolism, detailed understanding of the regulation of NR4A ac-
tivity will offer new opportunities to manipulate the activity of these
transcription factors to eventually attenuate these processes. We here
demonstrate that Pin1 is a coactivator of Nur77, Nurr1 and NOR-1 and
increases Nur77, but not Nurr1 and NOR-1 protein levels by increas-
ing the protein half-life of this nuclear receptor.
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